However, there is conflicting evidence regarding the predictive power of CD34+/KDR+ cells in patients with CAD; while some studies have shown that the number of circulating CD34+/KDR+ cells predicts outcome in healthy individuals and patients with CAD[33,34], a comparative analysis in patients with ACS reported that the CD34+/CD133+ phenotype, but not the CD34+/KDR+ or the CD133+/KDR+ phenotype, is predictive of recurrent ACS or MACE[35]. This evidence concerns the gene CD34 and coronary artery disorder.